Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells

References

• Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villén J, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011; 332:1322 - 6; http://dx.doi.org/10.1126/science.1199484; PMID: 21659605
   PubMed Web of Science ®Google Scholar
• Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011; 332:1317 - 22; http://dx.doi.org/10.1126/science.1199498; PMID: 21659604
   PubMed Web of Science ®Google Scholar
• Yea SS, Fruman DA. Cell signaling. New mTOR targets Grb attention. Science 2011; 332:1270 - 1; http://dx.doi.org/10.1126/science.1208071; PMID: 21659593
   PubMed Web of Science ®Google Scholar
• Fasolo A, Sessa C. Current and future directions in mammalian target of rapamycin inhibitors development. Expert Opin Investig Drugs 2011; 20:381 - 94; http://dx.doi.org/10.1517/13543784.2011.541154; PMID: 21299441
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al, RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449 - 56; http://dx.doi.org/10.1016/S0140-6736(08)61039-9; PMID: 18653228
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27:3822 - 9; http://dx.doi.org/10.1200/JCO.2008.20.7977; PMID: 19581539
   PubMed Web of Science ®Google Scholar
• Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer 2010; 9:144; http://dx.doi.org/10.1186/1476-4598-9-144; PMID: 20537194
   PubMed Web of Science ®Google Scholar
• Wang Z, Iwasaki M, Ficara F, Lin C, Matheny C, Wong SH, et al. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 2010; 17:597 - 608; http://dx.doi.org/10.1016/j.ccr.2010.04.024; PMID: 20541704
   PubMed Web of Science ®Google Scholar
• Sutherland C, Leighton IA, Cohen P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 1993; 296:15 - 9; PMID: 8250835
   PubMed Web of Science ®Google Scholar
• Hur EM, Zhou FQ. GSK3 signalling in neural development. Nat Rev Neurosci 2010; 11:539 - 51; http://dx.doi.org/10.1038/nrn2870; PMID: 20648061
   PubMed Web of Science ®Google Scholar
• Zheng H, Saito H, Masuda S, Yang X, Takano Y. Phosphorylated GSK3beta-ser9 and EGFR are good prognostic factors for lung carcinomas. Anticancer Res 2007; 27:5B 3561 - 9; PMID: 17972518
   PubMed Web of Science ®Google Scholar
• Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009; 11:102 - 10; http://dx.doi.org/10.1007/s11912-009-0016-4; PMID: 19216841
   PubMed Web of Science ®Google Scholar
• Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005; 65:2422 - 32; http://dx.doi.org/10.1158/0008-5472.CAN-04-2440; PMID: 15781658
   PubMed Web of Science ®Google Scholar
• Dasmahapatra GP, Didolkar P, Alley MC, Ghosh S, Sausville EA, Roy KK. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin Cancer Res 2004; 10:5242 - 52; http://dx.doi.org/10.1158/1078-0432.CCR-03-0534; PMID: 15297428
   PubMed Web of Science ®Google Scholar
• Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C, et al. Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Prostate 2008; 68:965 - 74; http://dx.doi.org/10.1002/pros.20757; PMID: 18361408
   PubMed Web of Science ®Google Scholar
• Nyåkern M, Cappellini A, Mantovani I, Martelli AM. Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther 2006; 5:1559 - 70; http://dx.doi.org/10.1158/1535-7163.MCT-06-0076; PMID: 16818515
   PubMed Web of Science ®Google Scholar
• Fu L, Kim YA, Wang X, Wu X, Yue P, Lonial S, et al. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res 2009; 69:8967 - 76; http://dx.doi.org/10.1158/0008-5472.CAN-09-2190; PMID: 19920197
   PubMed Web of Science ®Google Scholar
• Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107:4053 - 62; http://dx.doi.org/10.1182/blood-2005-08-3434; PMID: 16418332
   PubMed Web of Science ®Google Scholar
• Elrod HA, Lin YD, Yue P, Wang X, Lonial S, Khuri FR, et al. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther 2007; 6:2029 - 38; http://dx.doi.org/10.1158/1535-7163.MCT-07-0004; PMID: 17604333
   PubMed Web of Science ®Google Scholar
• Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, et al. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2008; 22:147 - 60; http://dx.doi.org/10.1038/sj.leu.2404980; PMID: 17928881
   PubMed Web of Science ®Google Scholar
• Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, Chiarini F, et al. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res 2008; 68:9394 - 403; http://dx.doi.org/10.1158/0008-5472.CAN-08-2815; PMID: 19010914
   PubMed Web of Science ®Google Scholar
• Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 2008; 68:7409 - 18; http://dx.doi.org/10.1158/0008-5472.CAN-08-1522; PMID: 18794129
   PubMed Web of Science ®Google Scholar
• Wang X, Hawk N, Yue P, Kauh J, Ramalingam SS, Fu H, et al. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy. Cancer Biol Ther 2008; 7:1952 - 8; http://dx.doi.org/10.4161/cbt.7.12.6944; PMID: 18981735
   PubMed Web of Science ®Google Scholar
• Wang X, Sun SY. Enhancing mTOR-targeted cancer therapy. Expert Opin Ther Targets 2009; 13:1193 - 203; http://dx.doi.org/10.1517/14728220903225008; PMID: 19694499
   PubMed Web of Science ®Google Scholar
• Wang X, Yue P, Chan CB, Ye K, Ueda T, Watanabe-Fukunaga R, et al. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol 2007; 27:7405 - 13; http://dx.doi.org/10.1128/MCB.00760-07; PMID: 17724079
   PubMed Web of Science ®Google Scholar
• Wang X, Hawk N, Yue P, Kauh J, Ramalingam SS, Fu H, et al. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy. Cancer Biol Ther 2008; 7:1952 - 8; http://dx.doi.org/10.4161/cbt.7.12.6944; PMID: 18981735
   PubMed Web of Science ®Google Scholar
• Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003; 2:1093 - 103; PMID: 14617782
   PubMed Web of Science ®Google Scholar
• Witzig TE, Kaufmann SH. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 2006; 7:285 - 94; http://dx.doi.org/10.1007/s11864-006-0038-1; PMID: 16916489
   PubMedGoogle Scholar
• Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 2010; 9:963 - 75; http://dx.doi.org/10.1158/1535-7163.MCT-09-0763; PMID: 20371718
   PubMed Web of Science ®Google Scholar
• Martinez A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med Res Rev 2008; 28:773 - 96; http://dx.doi.org/10.1002/med.20119; PMID: 18271054
   PubMed Web of Science ®Google Scholar
• Patel S, Woodgett J. Glycogen synthase kinase-3 and cancer: good cop, bad cop?. Cancer Cell 2008; 14:351 - 3; http://dx.doi.org/10.1016/j.ccr.2008.10.013; PMID: 18977324
   PubMed Web of Science ®Google Scholar
• Stambolic V, Woodgett JR. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J 1994; 303:701 - 4; PMID: 7980435
   PubMed Web of Science ®Google Scholar
• Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65:7052 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-05-0917; PMID: 16103051
   PubMed Web of Science ®Google Scholar
• Wang L, Lin HK, Hu YC, Xie S, Yang L, Chang C. Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells. J Biol Chem 2004; 279:32444 - 52; http://dx.doi.org/10.1074/jbc.M313963200; PMID: 15178691
   PubMed Web of Science ®Google Scholar
• Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, García-Echeverría C, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A 2009; 106:268 - 73; http://dx.doi.org/10.1073/pnas.0810956106; PMID: 19116269
   PubMed Web of Science ®Google Scholar
• Liao X, Zhang L, Thrasher JB, Du J, Li B. Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther 2003; 2:1215 - 22; PMID: 14617795
   PubMed Web of Science ®Google Scholar